abgÅ·²©

abgÅ·²©¿Æ¼¼Ó뿵ϣŵÉúÎï¸æ¿¢Õ½ÂÔºÏ×÷ ¹²Ì½mRNAÒßÃçÖ×ÁöÃâÒßмƻ®

2025-04-10

×ÖºÅ

       ¿ËÈÕ£¬abgÅ·²©¿Æ¼¼È«×Ê×Ó¹«Ë¾Ìì½òabgÅ·²©¿Æ¼¼ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°abgÅ·²©¿Æ¼¼¡±£©Ó뿵ϣŵÉúÎï×Ó¹«Ë¾¿µÏ£ÅµÉúÎÉϺ££©ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°¿µÏ£ÅµÉúÎ£©Ç©ÊðºÏ×÷¿ª·¢Ð­Ò飬˫·½½«ÅäºÏÍƽømRNAÒßÃçÓÃÓÚÖÎÁƽºÖÊĸϸ°ûÁö£¨GBM£©µÄÁÙ´²Ñо¿ÏîÄ¿£¬Ô¤¼Æ½ñÄêÄÚÍê³ÉÊ×Àý»¼Õ߸øÒ©¡£

       abgÅ·²©¿Æ¼¼ºÍ¿µÏ£ÅµÉúÎïͬΪÌì½òºËËṤҵͬÃ˵ijÉÔ±µ¥Î»£¬´ËÇ°Ë«·½ÔÚÒªº¦ÖÊÁÏÑз¢¼°½¹µãÊÖÒÕ֪ʶ²úȨ½á¹¹µÈÁìÓòÒѽ¨ÉèÓÅÒìºÏ×÷»ù´¡¡£±¾´ÎºÏ×÷½«³ä·ÖÑéÕ¹abgÅ·²©¿Æ¼¼ÔÚ¿¹Ö×ÁöÒ©Î￪·¢µÄ¸»ºñÂÄÀúÓ뿵ϣŵÉúÎïmRNAÊÖÒÕƽ̨µÄÐÛºñʵÁ¦£¬Í¬Ê±Ò²ÎªË«·½ÔÚmRNAÒßÃçÖÎÁÆÖ×ÁöÁìÓòÉîÈë½»Á÷ºÍ½øÒ»²½ºÏ×÷µÓÚ¨»ù´¡¡£

       abgÅ·²©¿Æ¼¼ÖÕÄêרעÓÚÒ©ÎïµÝËÍÁìÓò£¬ÔÚÖ×ÁöÃâÒß·½ÃæºÍmRNAµÝË͵ÈÆ«Ïò¾ùÓнṹ¡£abgÅ·²©¿Æ¼¼×ÔÖ÷Ñз¢µÄ¾ÛÒÒ¶þ´¼ÒÁÁ¢Ì濵(JK1201I)ÖÎÁÆÒ»ÏßÏ£ÍûÆÕ±éÆÚСϸ°û·Î°©ÕýÔÚ¾ÙÐÐÁÙ´²ÈýÆÚÑо¿£¬ÄÔ½ºÖÊÁö˳Ӧ֢Óë°éÄÔתÒƵÄÈýÒõÐÔÈéÏÙ°©Ë³Ó¦Ö¢ÕýÔÚ¾ÙÐÐÁÙ´²¶þÆÚÑо¿¡£

       ¿µÏ£ÅµÉúÎｨÉèµÄmRNAÊÖÒÕƽ̨£¬ÓµÓÐ×ÔÖ÷Éè¼Æ¡¢¿ª·¢µÄÐòÁÐÓÅ»¯Èí¼þ£¬¿É»ñµÃÓ°ÏìÎȹÌÐÔµÄÒªº¦Î»µã¼°ÓÐÓÃÌá¸ß¿¹Ô­±í´ïÁ¿µÄ×îÓÅÐòÁУ¬CMC¹¤ÒÕ¾«Á·£¬¿ÉÒÔËõ¶Ì²úÆ·¿ª·¢Ê±¼ä£¬¿ìËÙʵÏÖ¿ÆÑÐЧ¹û¹¤Òµ»¯¡£

       abgÅ·²©¿Æ¼¼½«ÒÀÍÐmRNAµÈÏȽøÊÖÒÕƽ̨£¬³Ð¼ÌÒÔÖÊÁÏÁ¢ÒìÒýÁìÉúÎïÒ½Ò©Á¢ÒìµÄʹÃü£¬Ò»Á¬Í¨¹ýÐÂÐÍÒ©ÎïµÝËÍÊÖÒÕΪÖ×ÁöÃâÒß¡¢»ùÒòÖÎÁƵÈÁìÓò´øÀ´¸ü¶àÓÐÖúÓÚÈ«·½Î»ÌáÉý»¼Õ߸£ÀûµÄ½â¾ö¼Æ»®£¬Ð¯ÊÖЭ×÷»ï°éÅäºÏÔö½ø¡°ÈËÈËÏíÓÐÎÀÉú¿µ½¡¡±Ä¿µÄµÄʵÏÖ¡£

 

¹ØÓÚ½ºÖÊĸϸ°ûÁö

½ºÖÊĸϸ°ûÁö£¨Ò²³ÆΪ¢ô¼¶ÐÇÐÎϸ°ûÁö£©ÊÇÌìÏÂÎÀÉú×éÖ¯È϶¨µÄIV¼¶½ºÖÊÁö£¬Ò²ÊÇ×î³£¼ûµÄ¶ñÐÔÔ­·¢ÐÔÄÔÖ×Áö£¬5ÄêÉúÑÄÂÊΪ7.2%¡£¸ÃÖ×ÁöÉú³¤Ñ¸ËÙ£¬¶ñÐԶȸߣ¬Ö÷ҪλÓÚ´óÄÔ°ëÇò£¬Ò²¿É±¬·¢ÔÚÄԸɡ¢Ð¡ÄÔ°ëÇò»ò¼¹ËèµÈ£¬Ö÷Òª·¢²¡ÄêËêΪ45-60Ë꣬ÄÐÐÔ½ÏÅ®ÐÔ·¢²¡ÂÊÂԸߣ¬¶ùͯҲ¿ÉÒÔ·¢²¡£¬ÇÒ¶à¼ûÓÚÄԸɡ£GBMµÄ¸ß¶È½þÈóÐÔ¡¢ÒÅ´«ÒìÖÊÐÔºÍѪÄÔÆÁÕϵı £»¤¸øÖÎÁÆ´øÀ´ÁËÖØ´óµÄÌôÕ½¡£ÏÖÔÚGBMµÄ±ê×¼ÖÎÁÆÊÇÊÖÊõÇгýºó¾ÙÐзŻ¯ÁÆ¡£ÊÖÊõÇгýÖ×Áöºó¸´·¢½Ï¿ì£¬ÆäÔ¤ºóÊÇÄÔ½ºÖÊÁöÖнϲîµÄÒ»ÖÖ¡£¡¾1¡¿

½üÄêÀ´ÃâÒßÁÆ·¨³ÉΪÐí¶àÖ×ÁöµÄÖ÷ÒªÖÎÁÆ·½·¨£¬¿ÉÊÇÔÚÄÔ°©£¨°üÀ¨GBM£©µÄÖÎÁÆÉÐδȡµÃÍ»ÆÆ¡£È¥ÄêÍâÑó¼¸ÏîʹÓÃmRNAÒßÃçµÄСÐÍÁÙ´²ÊÔÑéµÄЧ¹ûËƺõŤתÁËÕâÒ»Ç÷ÊÆ£¬Ïà¹ØµÄÑо¿±¨µÀÔÚNIHÉÏÓÐËù±¨µÀ[2]¡£Í¬Äêһƪ½ÒÏþÔÚJ NanobiotechnologyµÄ×ÛÊö»ã×ÜÁËmRNAÒßÃçÔÚGBMµÄÓ¦Óá¾3¡¿£¬Õ¹Ê¾ÁËÖ÷ÒªµÄÖÎÁÆDZÁ¦¡£

 

¹ØÓÚabgÅ·²©¿Æ¼¼

abgÅ·²©£¨abgÅ·²©¿Æ¼¼688356.SH£©½¨ÉèÓÚ2001Ä꣬ÊÇÈ«ÇòÒ½ÓÃÒ©ÓþÛÒÒ¶þ´¼ÖÊÁÏÁìÓòµÄÖ÷ÒªÐÂÐ˼ÓÈëÕߣ¬Îª¶à¿îÉÏÊÐPEG»¯Á¢ÒìÒ©Îï¼°Ò½ÁÆÆ÷е²úÆ·¹©Ó¦PEGÑÜÉúÎͬʱ¿ª·¢Á˺£ÄÚµÚÒ»¿îPEGżÁªÐ¡·Ö×ÓÒ©ÎÏÖÔÚ¸ÃÏîÄ¿´¦ÓÚÈýÆÚÁÙ´²½×¶Î¡£abgÅ·²©¿Æ¼¼¾Û½¹mRNAµÝËÍϵͳ½¹µãÊÖÒÕ¹¥¹Ø£¬ÔÚÒªº¦Ö¬ÖÊÖÊÁÏÁìÓòÈ¡µÃÖ÷ҪͻÆÆ£ºÍ¨¹ý¶ÔÏÖÓеÝËÍϵͳÖÐÒªº¦Ö¬ÖÊÒòËؾÙÐÐÉú²ú¹¤ÒÕÓÅ»¯£¬ÊµÏÖÁË5ÖÖÒªº¦¸¨ÁϵĹæÄ £»¯×ÔÖ÷ÖƱ¸£¬Ïà¹ØÊÖÒÕ×ÊÁÏÒÑͨ¹ý¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ºÍÃÀ¹úFDAµÄÖÊÁÏÒ©Ö÷Îļþ£¨DMF£©Ë«Öر¸°¸ £»Í¬²½¹¹½¨ÁË°üÀ¨ÊýÊ®ÖÖÁ¢Òì½á¹¹µÄÖ¬ÖÊ»¯ºÏÎï¿â£¬ÐγɾßÓÐ×ÔÖ÷֪ʶ²úȨµÄÊÖÒÕ¾ØÕó¡£

 

¹ØÓÚ¿µÏ£ÅµÉúÎï

¿µÏ£ÅµÉúÎï¹É·Ý¹«Ë¾£¨¿µÏ£ÅµÉúÎï 06185.HK £»¿µÏ£Åµ 688185.SH£©£¬2009Ä꽨ÉèÓÚÖйú£¬ÖÂÁ¦ÓÚÔÚÌìϹæÄ£ÄÚÌṩԤ·ÀºÍÖÎÁÆѬȾÀ༲²¡µÄ½â¾ö¼Æ»®¡£¹«Ë¾ÏÖÓв¡¶¾ÔØÌåÒßÃçÊÖÒÕ¡¢ºÏ³ÉÒßÃçÊÖÒÕ¡¢ÂѰ׽ṹÉè¼ÆºÍVLP×é×°ÊÖÒÕ¡¢mRNAÊÖÒÕ¡¢ÖƼÁ¼°¸øÒ©ÊÖÒÕÎå´óÁ¢ÒìÒßÃçƽ̨ÊÖÒÕ¡£ÏÖÔÚÒѽ¨ÉèÁýÕÖ10ÓàÖÖ˳Ӧ֢µÄ¶à¿îÁ¢ÒìÒßÃç²úÆ·£¬°üÀ¨ÑÇÖÞÊ׿îËļÛÁ÷ÄÔÍŽáÒßÃçÂüº£ÐÀ?¡¢¶þ¼ÛÁ÷ÄÔÍŽáÒßÃçÃÀÄÎϲ?¡¢»ñµÃÊÀÎÀ×éÖ¯ÈϿɵÄйÚÒßÃç¿ËÍþɯ?¡¢È«ÇòÊ׿îÎüÈëÓÃйÚÒßÃç¿ËÍþɯ?ÎíÓÅ?ÒÔ¼°ÑÇÖÞÊ׸öÖØ×é°£²©À­²¡¶¾²¡ÒßÃç¡£

 

Reference

[1] Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021 Sep;171:105780. doi: 10.1016/j.phrs.2021.105780. Epub 2021 Jul 21. PMID: 34302977; PMCID: PMC8384724.

[2] mRNA Vaccine Boosts Immune Response Against Glioblastoma - NCI

[3] Karimi-Sani I, Molavi Z, Naderi S, Mirmajidi SH, Zare I, Naeimzadeh Y, Mansouri A, Tajbakhsh A, Savardashtaki A, Sahebkar A. Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials. J Nanobiotechnology. 2024 Oct 4;22(1):601. doi: 10.1186/s12951-024-02882-x. PMID: 39367418; PMCID: PMC11453023.

Òªº¦´Ê£º

ÉÏÒ»Ò³

ϲ±¨ | abgÅ·²©¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

abgÅ·²©¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

ÏÂÒ»Ò³

ÉÏÒ»Ò³£º

ϲ±¨ | abgÅ·²©¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

ÏÂÒ»Ò³£º

abgÅ·²©¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

ÍƼöÐÂÎÅ

¡¾abgÅ·²©¿Æ¼¼×¨Ìâ·ÖÏí¡¿ÓëÄúÏàÔ¼6ÔÂCPHIÖÆÒ©ÖÊÁÏÖÇÔ칤ҵÂÛ̳

2025-06-09

ϲ±¨ | abgÅ·²©¿Æ¼¼£¨688356.SH£©×¢ÉäÓý»ÁªÍ¸Ã÷ÖÊËáÄÆÄý½º²úÆ·»ñÅúÈýÀàÒ½ÁÆÆ÷еע²áÖ¤

2025-04-27

abgÅ·²©¿Æ¼¼£¨688356.SH£©KT-001ºÍHO-PEG2000-DMG»®·Öͨ¹ýFDA¡¢CDE±¸°¸

2025-03-06

·ÖÏíµ½

ÍøÕ¾µØͼ